SML3405
NVP-LDZ982
≥98% (HPLC)
Synonym(s):
LDZ-982, LDZ 982, LDZ982, Methyl 5-[1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, NITD 982, NITD-982, NITD982
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H11Cl3F3N3O3
CAS Number:
Molecular Weight:
516.68
NACRES:
NA.77
UNSPSC Code:
12352200
assay
≥98% (HPLC)
form
powder
color
, Light yellow to orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Dihydroorotate dehydrogenase (DHODH) inhibitor with broad-spectrum antiviral activity against Dengue, HCV, HIV, Influenza, RSV, and Yellow fever.
NVP-LDZ982 (NITD-982) is a dihydroorotate dehydrogenase (DHODH) inhibitor (Kd = 27 nM) with broad-spectrum antiviral activity by targeting host cell de novo pyrimidine biosynthesis pathway. NITD-982 inhibits various viral replications in cultues, including Dengue (DENV EC50 = 5-2.6 nM; A549), hepatitis C virus (HCV EC50 = 7-12.6 nM; Huh-7), HIV (MDR769 EC50 = 0.97 nM; PBMC), Influenza (EC50 = 32 nM/H1N1, 117 nM/B, 217 nM/H1N3; MDCK), respiratory syncytial virus (RSV EC50 = 7-9 nM; Hep-2), and Yellow fever (strain 17D EC50 = 8.2 nM; A549).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Inhibition of dengue virus through suppression of host pyrimidine biosynthesis
Journal of Virology, 85(13), 6548-6556 (2011)
Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)
Proceedings of the National Academy of Sciences of the USA, 108(17), 6739-6744 (2011)
Kim Long Yeo et al.
Antimicrobial agents and chemotherapy, 59(4), 2086-2093 (2015-01-28)
Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service